Risk Sharing Agreement Pharma

Cheema PK, Gavura S, Godman B, Yeung L, Trudeau ME. Global differences in the reimbursement of new cancer drugs: improved access through risk-sharing agreements. J Clin Oncol. 2010; 28 (15_suppl): 6050. ascopubs.org/doi/abs/10.1200/jco.2010.28.15_suppl.6050. Access on April 13, 2015. Other supply-and-demand initiatives are essential if Europe is to maintain the ideals of socially funded and equitable health care. This could mean a further extension of risk-sharing systems. A number of documents have recently been published, in which existing and historical risk-sharing systems have been fully reviewed, proposing proposals for the future [5, 10, 20, 34, 36, 39]. However, the terminology remains very confusing and needs to be addressed as a matter of urgency. Public health staff are also concerned about the level of administrative intensity associated with some of the current regimes and, ultimately, they could contribute significantly to the costs of developing new molecules [5, 40, 41]. Certainly, in the past, much of the risk associated with the results of coverage decisions has been borne by health authorities and insurance companies [34].

Given the number of costly new technologies implemented in conjunction with their budgetary impact [6, 23, 34], this is beginning to change. These challenges are reinforced by the lack of scientific studies evaluating the implementation and results of many existing pharmaceutical systems in terms of total cost and utility [10, 34]. This has not been the case for non-pharmacological technologies, which have so far resulted in 17 policy outcomes from 32 mainly non-drug technologies, of which about 60% of cases correspond to the results of the systems study [34]. We believe that these concerns need to be discussed and discussed before "risk-sharing systems" continue to increase. This document aims to stimulate this debate by: in short, payers adopt risk-sharing agreements to improve the cost-effectiveness of new therapies. This will be achieved by reducing uncertainty about drug performance and the impact on costs. For a pharmaceutical company, risk-sharing agreements are a mechanism to maintain or accelerate market access by allaying the concerns of payers. Outside the United States, it is also a mechanism for manufacturers to protect prices by offering return discounts, which reduces the global impact due to reference prices. Petrov M, Hubenov P.

Introduction of formal risk-sharing agreements (RSA): a promising solution for sustainable and predictable pharmaceutical spending in Bulgaria. Health value. 2015;18 (7):A571-2. Folino Gallo P, Deambrosis P: Pharmaceutical risk sharing and conditional reimbursement in Italy. 2008, Krakow (access 3 March 2010), [www.ceestahc.org/pliki/symp2008/gallo.pdf] In Italy, RSA has become a standard procedure for access to the Italian market, and a recent study by Tettamanti et al. [56], AIFA and local resources evaluated 82 therapies from 2006 to 2015. More than half of treatments (59%) through a PBRSA, 33% were financial and 1% were using both systems [56]. According to the data, PBRSAs have slowly replaced RSA over the years and account for 78% of the total [56].